CFM
DGX icon

Catalyst Funds Management’s Quest Diagnostics DGX Stock Holding History

Catalyst Funds Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,065
Closed -$209K – 717
2026
Q1 		$209K Buy
+1,065
New +$207K 0.04% 446
2024
Q4 		– Sell
-400
Closed -$62.1K – 578
2024
Q3 		$62.1K Sell
400
-500
-56% -$74.7K 0.01% 696
2024
Q2 		$123K Buy
900
+700
+350% +$95.9K 0.03% 256
2024
Q1 		$26.6K Buy
+200
New +$25.9K 0.01% 695

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Catalyst Funds Management's DGX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 1,065 shares — an estimated $209K sold.

Catalyst Funds Management first reported a position in DGX in Q1 2024 and held it in 4 quarters. The position peaked at $209K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 1,065 Quest Diagnostics shares in Q2 2026, an estimated $209K.
  • Catalyst Funds Management first reported a position in Quest Diagnostics in Q1 2024 and held it in 4 quarters.
  • Catalyst Funds Management's Quest Diagnostics position peaked at $209K in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.